Viscofan World You are in: The Viscofan Group EN | ES
Global

The Viscofan Group

EN | ES
Europe

Belgium

EN

Czech Republic

CS | EN

Germany

DE

Serbia

EN | SR

Spain

ES
Americas

Brazil

PT

Canada

EN | FR

Mexico

ES

United States

EN

Uruguay

ES
Asia & Oceania
Viscofan BioEngineering
Viscofan Group releases its 1H25 results
30/July/2025

Main conclusions from the January-June 2025 results

• €311.5 million of quarterly revenue, an increase of 2.7% compared to the previous year driven by the acceleration in the growth of casing volumes and the recovery of new business against the negative impact of the depreciation of the US$ against the €, up to a total accumulated revenue to June of €618.8 million.

• Quarterly EBITDA of €76.3 million, up 9.0% year-over-year and with a 1.4 p.p. improvement in the EBITDA margin to 24.5%, bringing the year-to-date EBITDA to €145.2 million.

• Net profit of €38.4 million in the quarter, up 3.1% year-on-year, reaching a total of €69.8 million for the period.

• Net bank debt as of June 2025 stands at €228.7 million (€146.9 million as of December 2024), including the €28.8 million payment in June to shareholders who have opted to receive the Final Dividend in cash, and the €49.1 million cash outflow from the share repurchase carried out under the flexible retribution program.

• For José Antonio Canales, CEO of the Viscofan Group:

"We have achieved solid results driven by the acceleration in casing volumes, production efficiencies, and cost savings. Operating performance is in line with the full-year guidance announced in February, with the exception of the US$ versus the €, which limits the full transfer of this improvement to net profit."

All results information is available on the Investor Relations site. LINK

® Viscofan Group